Bachem Holding AG (SWX:BANB)
Switzerland · Delayed Price · Currency is CHF 77.10
-0.10 (-0.13%)
May 13, 2026, 5:15 PM CET
Bachem Holding AG Revenue
In the year 2025, Bachem Holding AG had annual revenue of 695.07M CHF with 14.84% growth. Bachem Holding AG had revenue of 382.08M in the half year ending December 31, 2025, with 13.22% growth.
Revenue
695.07M
Revenue Growth
+14.84%
P/S Ratio
8.32
Revenue / Employee
294.15K
Employees
2,595
Market Cap
5.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 695.07M | 89.81M | 14.84% |
| Dec 31, 2024 | 605.26M | 27.94M | 4.84% |
| Dec 31, 2023 | 577.32M | 45.58M | 8.57% |
| Dec 31, 2022 | 531.74M | 28.51M | 5.66% |
| Dec 31, 2021 | 503.23M | 101.24M | 25.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Basilea Pharmaceutica AG | 232.38M |
| Idorsia | 220.58M |
| Santhera Pharmaceuticals Holding AG | 77.19M |
| Newron Pharmaceuticals | 17.81M |
| BioVersys AG | 3.18M |
| Molecular Partners AG | 681.00K |
| Xlife Sciences AG | 275.31K |
| Addex Therapeutics | 173.00K |
Bachem Holding AG News
- 2 months ago - Bachem Holding AG Earnings Call Transcript: H2 2025 - Transcripts
- 10 months ago - Bachem Holding AG Earnings Call Transcript: H1 2025 - Transcripts